Arabic Arabic English English French French German German
dark

Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in China

Basilea Pharmaceutica Ltd. announced that its license partner, Pfizer Inc., has received a Drug Approval License from the National Medical Products Administration in China, for the oral formulation of its antifungal Cresemba® for the treatment of adult patients with invasive aspergillosis. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Yorkshire and Humber AHSN showcase innovations to senior NHS figures

Next Post

Evasc Neurovascular Announces Enrollment of First Patient in the French eCLIPs™ Safety, Feasibility and Efficacy Study (EESIS-FR)

Related Posts
Total
0
Share